Researchers devise a progression risk-based classification for patients with AWM

(Dana-Farber Cancer Institute) Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenstr ö m macroglobulinemia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news